Company news

Coherus Oncology, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

May 8, 2024

Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer

May 7, 2024

Coherus to Report First Quarter 2024 Financial Results on May 9, 2024

April 30, 2024

Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

April 23, 2024

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

March 12, 2024

Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

March 4, 2024

Coherus Completes Divestiture of Ophthalmology Franchise

March 3, 2024

Coherus BioSciences Announces New Employment Inducement Grants

February 22, 2024

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

February 20, 2024

Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP

February 4, 2024

Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal

January 21, 2024

Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium

January 17, 2024

Coherus Announces U.S. Launch of LOQTORZI™

January 1, 2024

Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

December 25, 2023

Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx

December 10, 2023

Coherus BioSciences Announces CFO Transition Plans

December 6, 2023

Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress

December 5, 2023

Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights

November 5, 2023

Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)

November 2, 2023

Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023

October 29, 2023

Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

October 26, 2023

Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 13, 2023

Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™

October 4, 2023

CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch

October 3, 2023

Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

September 26, 2023

FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections

September 24, 2023

Coherus Completes Surface Oncology Acquisition

September 7, 2023

Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights

August 1, 2023

Coherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023

July 25, 2023

Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors

July 19, 2023

Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™

July 12, 2023

Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.

July 2, 2023

Coherus to Acquire Surface Oncology

June 15, 2023

Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma

June 4, 2023

Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023

May 31, 2023

Coherus Announces U.S. Launch of UDENYCA® Autoinjector

May 21, 2023

Coherus Prices Public Offering of Common Stock

May 15, 2023

Coherus Announces Proposed Public Offering of Common Stock

May 14, 2023

Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights

May 7, 2023

Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023

April 30, 2023

Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

April 26, 2023

FDA Approves UDENYCA® Autoinjector

March 5, 2023

Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results

March 5, 2023

Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

February 27, 2023

Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

February 14, 2023

Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services

February 12, 2023

Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma

January 8, 2023

Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update

November 7, 2022

Coherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022

October 31, 2022

Coherus to Launch CIMERLI™ (ranibizumab-eqrn) in the United States on October 3, 2022

September 18, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 29 calls. Every call is listed under its year.

Decks